Prognostic Significance of EMVI in Rectal Cancer in a Tertiary Cancer Hospital in India

Sayali Y. Pangarkar1,2 Akshay D. Baheti1 Kunal A. Mistry1,2 Amit J. Choudhari1,2 Vasundhara R. Patil1,2 Ankita Ahuja1,2 Aparna N. Katdare1,2 Akshay B. Patil3 Vikas S. Ostwal2,4 Mukta R. Ramadwar2,5 Reena Z. Engineer2,6 Avanish P. Saklani2,7

1 Department of Radio-diagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
2 Homi Bhabha National Institute, Mumbai, Maharashtra, India
3 Division of Clinical Research and Statistics, Tata Memorial Hospital, Mumbai, Maharashtra, India
4 Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
5 Department of Pathology Tata Memorial Centre, Mumbai, Maharashtra, India

Abstract

Background Presence of extramural venous invasion (EMVI) is a poor prognostic factor for rectal cancer as per literature. However, India-specific data are lacking.

Aim The aim of the study is to determine the prognostic significance of EMVI in locally advanced rectal cancer on baseline MRI.

Materials and Methods We retrospectively reviewed 117 MRIs of operable non-metastatic locally advanced rectal cancers in a tertiary cancer institute. Three dedicated oncoradiologists determined presence or absence of EMVI, and its length and thickness, in consensus. These patients were treated as per standard institutional protocols and followed up for a median period of 37 months (range: 2–71 months). Kaplan-Meier curves (95% CI) were used to determine disease-free survival (DFS), distant-metastases free survival (DMFS), and overall survival (OS). Univariate analysis was performed by comparing groups with log-rank test.

Results EMVI positive cases were 34/114 (29%). More EMVI-positive cases developed distant metastasis compared with EMVI-negative cases (14/34 – 41% vs. 22/83 – 26%). The difference, however, was not statistically significant (p = 0.146). After excluding signet-ring cell cancers (n = 14), EMVI showed significant correlation with DMFS (p = 0.046), but not with DFS or OS. The median thickness and length of EMVI was 6 and 14 mm, respectively in patients who developed distant metastasis, as compared with 5 and 11 mm in those who did not, although this difference was not statistically significant.

Conclusion EMVI is a predictor of distant metastasis in locally advanced non-metastatic, non-signet ring cell rectal cancers. EMVI can be considered another high-risk feature to predict distant metastasis.

Keywords
► extramural venous invasion
► MRI
► rectal cancer

Indian J Radiol Imaging 2021;31:560–565.

**Introduction**

Colorectal cancer is a common cancer affecting the Indian population, with up to 30% being upfront metastatic.\(^1,2\) The signet ring cell variety of rectal carcinoma is particularly aggressive, with a high propensity for peritoneal metastasis and involvement of a younger age group.\(^3,4\) Although the worldwide incidence of this histologic variant is 1%, Indian population shows a higher incidence varying from 11 to 13% in different studies.\(^2,5\)

Extramural venous invasion (EMVI) i.e., spread of tumor into perirectal vessels, is an established risk factor for distant metastasis, with reduced disease-free survival (DFS) and overall survival (OS).\(^6-\)\(^8\) Our literature search did not show any imaging study in the Indian population with regards to the significance of EMVI in rectal cancer. This would be interesting to see because of the frequently seen advanced disease at presentation and the higher proportion of signet ring cell cases in the Indian population, increasing the confounding factors for poor outcomes. Furthermore, while EMVI has prognostic significance, it is possible that patients with thicker and longer extent of involvement have a worse prognosis compared with patients with mild involvement.\(^8,9\)

Thus, the objective of our study was to determine the prognostic significance of EMVI in rectal cancers in the Indian population, and to evaluate whether the length and thickness of involvement correlated with prognosis.

**Materials and Methods**

**Subjects**

This is an Institutional Review Board approved retrospective study. We identified 166 consecutive cases of operable non-metastatic pathologically proven rectal cancer from our colorectal disease management group database from the year 2011 to 2015. Patients presenting with non-metastatic rectal cancer and baseline MRI available were included in the study. MRI performed in outside institutes was included if DICOM images were available on PACS. Exclusion criteria were suboptimal image quality, patients that progressed during the neoadjuvant chemoradiation and did not undergo curative treatment, and patients lost to follow-up.

**Clinical and Histopathology Data**

The patient demographic data, histopathology, treatment, and follow-up details were extracted from the institutional electronic medical records. All definitive surgeries were performed by dedicated gastrointestinal oncologists at our institute. All patients were treated with neoadjuvant chemoradiation (CTRT) followed by definitive surgery and were followed up for a median period of 37 months (range: 2–71 months).

**Imaging and Image Analysis**

MR images were acquired on 1.5T (GE Healthcare, Milwau-kee, United States), 1.5T (Philips Medical Systems, Eind- hoven, Netherlands), or 3T (GE Healthcare, Milwaukee, United States) machines in our institute using the institu-
Results

A total of 117 patients were included in the study (Fig. 4). 45/117 (38.5%) cases were females and 72 (61.5%) were males with a median age of 51 years. The baseline characteristics of the patients are given in Table 1. EMVI was present in 34/117 (29%) cases and absent in 83 (71%) cases. Twelve patients had grade 3 EMVI and 22 had grade 4 EMVI. Overall, 36/117 (30%) developed distant metastasis. 15/117 (12.8%) developed local recurrence, with 8/15 of these also having distant metastasis (Table 2). Three-year DFS and OS were 67 and 82%, respectively in EMVI positive cases, compared with 74 and 82% in EMVI negative cases. However, this did not reach statistical significance (Table 3; Figs. 5 and 6).

Table 1 Baseline characteristics of primary tumor determined on MRI

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Stage</th>
<th>No. of patients out of n = 117</th>
</tr>
</thead>
<tbody>
<tr>
<td>mrT stage</td>
<td>&lt;T3</td>
<td>6 (5%)</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>91 (78%)</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>20 (17%)</td>
</tr>
<tr>
<td>mrN stage</td>
<td>N0</td>
<td>25 (21%)</td>
</tr>
<tr>
<td></td>
<td>N1</td>
<td>51 (44%)</td>
</tr>
<tr>
<td></td>
<td>N2</td>
<td>41 (35%)</td>
</tr>
<tr>
<td>mrCRM status</td>
<td>Positive</td>
<td>63 (53.9%)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>54 (46.1%)</td>
</tr>
</tbody>
</table>

Table 2 Distribution of EMVI positive and negative cases and their correlation to distant metastases, local recurrence, and survival

<table>
<thead>
<tr>
<th>EMVI status</th>
<th>No. of cases</th>
<th>Grade of EMVI</th>
<th>No. of cases</th>
<th>Distant metastasis Grade-wise</th>
<th>Distant metastases (DM) Total</th>
<th>Local recurrence (LR) Total</th>
<th>Deaths total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>83/117</td>
<td>0</td>
<td>24</td>
<td>7</td>
<td>22/83 (26%)</td>
<td>10/83 (12%)</td>
<td>11/83 (13%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>49</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>10</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>34/117</td>
<td>3</td>
<td>12</td>
<td>2</td>
<td>14/34 (41%)</td>
<td>5/34 (14.7%)</td>
<td>7/34 (20.5%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>22</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fourteen out of 34 (41%) EMVI-positive cases developed distant metastasis, compared with 22/83 (26%) EMVI-negative cases (►Table 2). The difference, however, was not statistically significant ($p = 0.146$). After excluding signet-ring cell positive cases ($n = 14$), presence of EMVI showed significant correlation with distant metastasis free survival ($p = 0.046$) (►Fig. 7), with 12/29 (41%) cases with EMVI developing metastases compared with 16/74 (22%) patients without EMVI. However, there was no statistical difference in the overall DFS and OS (►Table 3).

The median thickness of EMVI was 6 mm and median length of EMVI was 14 mm in patients who developed distant metastasis, compared with 5 and 11 mm, respectively, in patients who did not develop distant metastasis. This was not statistically significant.

**Discussion**

MRI is the imaging modality of choice for staging and restaging of rectal cancer. The prognosis of rectal cancer in terms of survival and likelihood of recurrence depends on several factors such as histologic grade, T category, N category, CRM involvement, and EMVI.12–15

Traditionally, venous invasion was a histopathological concept.16 Many studies have shown pathological venous invasion to portend worse prognosis.17,18 A systematic review by Chand et al.'s19 of 14 pathological studies demonstrates venous invasion and more specifically EMVI to be associated with worse survival. The 5-year survival ranged from 20 to 33% in EMVI positive cases to 45 to 73% in EMVI negative cases.16,20,21

MRI has moderate sensitivity and good specificity for detecting EMVI.22 Multiple studies have demonstrated that mrEMVI correlates with worse prognosis.6,8,23–26 A recent meta-analysis of 1,262 patients demonstrated a prevalence of mrEMVI in about one-third patients, similar to our study.6

**Table 3** Three-year DFS and OS in EMVI positive and negative cases in entire study population and in the signet ring cell negative subset

<table>
<thead>
<tr>
<th>Patients</th>
<th>EMVI</th>
<th>3-y DFS</th>
<th>p</th>
<th>3-y OS</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases ($n = 117$)</td>
<td>Negative</td>
<td>74.2%</td>
<td>0.180</td>
<td>87%</td>
<td>0.211</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>67.2%</td>
<td></td>
<td>82%</td>
<td></td>
</tr>
<tr>
<td>Signet ring cell negative cases ($n = 103$)</td>
<td>Negative</td>
<td>79%</td>
<td>0.109</td>
<td>91%</td>
<td>0.22</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>72%</td>
<td></td>
<td>88.6%</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DFS, disease-free survival; EMVI, extramural venous invasion; OS, overall survival.
They found an almost fourfold increase in the risk of developing metastases in patients with mrEMVI present at baseline. Various studies demonstrate development of distant metastases in 6.7 to 23% mrEMVI negative cases compared with 24.5 to 55% in mrEMVI positive cases.24,27 Our India-specific data shows a similar trend, with 26% mrEMVI negative and 41% mrEMVI positive developing distant metastases. The percentage of mrEMVI negative patients developing subsequent metastatic recurrence is slightly higher than other studies; the reasons for this could include the higher incidence of signet cell tumors in the Indian population and possible relatively advanced tumors at the time of presentation.

Gu et al.28 found a 3-year DFS of 60% for mrEMVI scores 3 and 4 and 86% with mrEMVI scores 0 to 2. Similarly, in a study of 142 patients, Smith et al.24 observed a DFS of 35% at 3 years for patients with mrEMVI scores of 3 to 4, compared with 74% for those with mrEMVI 0 to 2. Our study results showed a 3-year DFS of 67% for EMVI 3 to 4 and 74% for EMVI grades 0 to 2, although this was not statistically significant.

There is mixed data with regards to correlation of mrEMVI with OS, with some studies not finding statistically significant correlation.28,29 While others demonstrating significantly worsened survival in mrEMVI positive patients,24,27 our study findings showed a 3-year OS of 82% for mrEMVI positive cases, which was lesser than the OS of 87% for mrEMVI negative patients, but not statistically significant.

India has a unique profile of rectal cancer presentation, with a high incidence of advanced cancers and aggressive signet ring tumors. In patients with such high-risk features at presentation, the degree of incremental worsening of prognosis due to the presence of mrEMVI is uncertain. We observed a nonsignificant trend to worsened prognosis in mrEMVI positive cases; the lack of significance could be due to the small numbers. EMVI showed significant correlation with DMFS (p = 0.046) when the signet ring cell cases were excluded, but again did not correlate with DFS or OS.

A pathological study has demonstrated strong correlation between venous invasion involving thick-walled veins rather than thin-walled veins with respect to the incidence of liver metastases.18 Bugg et al and Sohn et al.8,9 demonstrated that involvement of larger caliber vessels (≥3 mm) by EMVI leads to increased risk of metastasis. We similarly hypothesized that increased thickness and length of involvement of perirectal vessels by EMVI could correlate with a higher risk of metastases (Fig. 8). We did not observe a significant difference in the median length and thickness of EMVI of patients who developed distant recurrence and those who did not, although the median length and thickness were slightly higher in the former group. Our numbers were small, and larger studies would be needed to evaluate this finding further.

Our study had a few limitations. It was a retrospective study, although the radiologists were blinded to the histopathology and final outcome. The sample size was small with a limited number of EMVI positive cases. There may also be a referral bias as ours is a tertiary care cancer. Our institute protocol does not include contrast-enhanced study for rectal cancer cases. This is as per the Society of Abdominal Radiology (SAR) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) guidelines. However, some studies do suggest better detection of EMVI using gadolinium contrast enhanced sequences.30-34 Jhaveri et al. found that contrast-enhanced sequences helped in re-stratification of the equivocal Grade 2 EMVI cases which did not show overt tumor signal within a dilated vein. EMVI was seen as a partial or complete filling defect within the contrast-filled vessel lumen, which could then be re-classified as Grade 3 if present or Grade 1 if absent.11,34 The ESGAR panel opinion was that dynamic contrast enhanced sequence should be considered a research tool and not adopted in routine practice. The panel acknowledged that it may help in select cases to improve tumor conspicuity in the post-treatment setting and for the assessment of mucinous tumors.

In conclusion, we did not find a significant correlation between mrEMVI and DFS or OS in patients with non-metastatic disease at baseline, although a higher percentage of patients with EMVI developed distant recurrence compared with those without EMVI. Larger multicentric studies are needed to evaluate the significance of these findings. There was, however, a statistically significant worsening of DMFS in non-signet-ring cell cancers.

Financial Support and Sponsorship

None.

Conflict of Interest

None declared.

References

1 Consensus Document for Management of Colorectal Cancer ICMR, New Delhi; 2014:11–13


4 Chew MH, Yeo SA, Ng ZP, et al. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764